20+ YEARS OF eCOA EXPERIENCE ACROSS ALL THERAPY AREAS
Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.
Oncology-Focused eCOA That Goes Beyond Reliable Tech
High-quality, reliable data to support regulatory decision-making and labelling
ADDITIONAL RESOURCES
Address Changing Regulatory Requirements
Ready to revolutionize the way you conduct oncology trials? Get started today.
Rapid eCOA builds using our solution’s intuitive and collaborative design interface
Enhanced patient experience with built-in patient engagement features
Flexibility to capture data at home or at site to ensure optimal measurement strategy
What do you get when you partner with Signant?
Develop an eCOA measurement strategy that meets FDA requirements on measure specificity and schedule of administration
Work with scale authors to adapt sub-scales to derive more disease-specific measures
Optimize eCOA schedule of events to minimize patient completion burden
Enable new scale development using item banks
Oncology research today demands flexible, scalable data capture solutions as well as considerations to minimize participant and site burdens. Discover how Signant SmartSignals eCOA, backed by 20 years of oncology and eCOA science expertise, enables study teams to meet changing regulatory requirements and generate reliable clinical evidence at any scale while optimizing trial participation and conduct.
Signant Health eCOA Experience
90
LANGUAGES
COUNTRIES
55+
168k+
PATIENTS
45k+
SITES
STUDIES
330+
20+
YEARS
Signant Health's Oncology-Specific eCOA Experience
250
SCALES
40+
INDICATIONS
Signant has provided eCOA support in 27% of the novel oncology drugs approved by the FDA and the EMA in the US and EU over the last 6 years.